A study to determine tolerability of casirivimab and imdevimab therapy in pregnant women with COVID-19 compared with control group (women did not receive therapy) in Japan and its impact on neonate and process of delivery
Latest Information Update: 20 Sep 2022
Price :
$35 *
At a glance
- Drugs Casirivimab/imdevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 20 Sep 2022 New trial record
- 01 Sep 2022 Results published in the Journal of Obstetrics and Gynaecology Research